muc13 (Bioss)
Structured Review

Muc13, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/muc13/product/Bioss
Average 90 stars, based on 2 article reviews
Images
1) Product Images from "Polystyrene nanoplastics disrupt the intestinal microenvironment by altering bacteria-host interactions through extracellular vesicle-delivered microRNAs"
Article Title: Polystyrene nanoplastics disrupt the intestinal microenvironment by altering bacteria-host interactions through extracellular vesicle-delivered microRNAs
Journal: Nature Communications
doi: 10.1038/s41467-025-59884-y
Figure Legend Snippet: A Alcian blue-periodic acid Schiff (AB-PAS) staining of intestinal mucus in mice with or without NP treatment. Scale bars indicate 100 µm (upper) and 50 µm (lower). Data were shown as mea n ± SEM ( n = 12). B IHC stain of intestinal MUC-13 in NP-treated mice. Scale bars indicate 100 µm (upper) and 50 µm (lower). Data were shown as mea n ± SEM ( n = 12) (*** p value < 0.001). C MUC13 expression in NP-treated enterocyte-like differentiated Caco-2 cells for 48 h by ICC stain (Scale bars indicate 20 µm), qPCR, and Western blot. Data are presented as means ± SD ( n = 3). Significant difference was shown by different letters (* p < 0.05; *** p < 0.001). D Western blot analysis of MUC-13 levels in goblet-like LS174T cells treated with NP for 48 h. E Heatmap predicting various intestinal miRNAs suppressing MUC-13 in NP-exposed mice. Validation of miR-700-5p interference on MUC-13 in enterocyte-like differentiated Caco-2 cells by ( F ) qPCR. G ICC stain (Scale bars indicate 20 µm), and ( H ) Western blot. Data are presented as means ± SD ( n = 3). Significant difference was shown by different letters (*** p < 0.001). I Schematic of NP im p act on MUC-13 and mucus secretion in the gut.
Techniques Used: Staining, Expressing, Western Blot, Biomarker Discovery
Figure Legend Snippet: A The effects of NP treatment (1 × 10 10 particles/mL) on the growth of various lactic acid bacteria ( L. paracasei, L. acidophilus , and P. acidiloctici ) , Lachnospiraceae sp. (TSD-26; ATCC), and Ruminococcaceae sp. (TSD-27; ATCC). B Schematic of experimental process by interactions between bacterial EV and cell-derived EV. C Impact of Lachnospiraceae sp.-derived EV without or with NP treatment (1 × 10 10 particles/mL) for 18 h on the growth of different bacterial species ( L. paracasei , L. acidophilus , P. acidiloctici , and Ruminococcaceae sp.). D The impact of Ruminococcaceae sp.-derived EV without or with NP treatment (1 × 10 10 particles/mL) for 44 h on the growth of different bacterial species ( L. paracasei , L. acidophilus , P. acidiloctici , and Lachnospiraceae sp.). E Impact of goblet-like LS174T cells without or with NP treatment (10 6 particles/mL) for 48 h on the growth of different bacterial species ( L. paracasei, L. acidophilus, P. acidiloctici , and Lachnospiraceae sp. and Ruminococcaceae sp.). F Western blot of MUC13 inhibition by Lachnospiraceae sp.-derived EV. Data were shown as mea n ± SD ( n = 3) (* p value < 0.05). G Schematic representation summarizing the proposed mechanisms of NP-induced modulation of gut microbiota via EV. NP are taken up by Lachnospiraceae , whose EV suppress MUC13 expression in goblet cells. Concurrently, NP-modified EV from goblet cells promote the growth of Ruminococcaceae , collectively contributing to gut microbiota imbalance and potential intestinal barrier dysfunction.
Techniques Used: Bacteria, Derivative Assay, Western Blot, Inhibition, Expressing, Modification

